We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01144832
Recruitment Status : Completed
First Posted : June 16, 2010
Last Update Posted : January 28, 2016
Information provided by (Responsible Party):
Guy Boeckxstaens, Katholieke Universiteit Leuven

May 28, 2010
June 16, 2010
January 28, 2016
October 2009
May 2012   (Final data collection date for primary outcome measure)
Effect of treatment on visceral sensitivity measured with rectal barostat. [ Time Frame: after 12 weeks treatment ]
Same as current
Complete list of historical versions of study NCT01144832 on ClinicalTrials.gov Archive Site
Effect of treatment on IBS symptoms. [ Time Frame: after 12 weeks treatment ]
Same as current
Not Provided
Not Provided
Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
IBS Treatment With H1-receptor Antagonists


To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine.


Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).

End points:

End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.

Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Irritable Bowel Syndrome
  • Drug: ebastine
    20 milligram capsule once daily
  • Drug: placebo capsule
    one capsule once daily
  • Placebo Comparator: placebo capsule
    Intervention: Drug: placebo capsule
  • Active Comparator: ebastine
    Intervention: Drug: ebastine
Wouters MM, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W, Van der Merwe S, Mols R, Ghesquière B, Cirillo C, Kortekaas I, Carmeliet P, Peetermans WE, Vermeire S, Rutgeerts P, Augustijns P, Hellings PW, Belmans A, Vanner S, Bulmer DC, Talavera K, Vanden Berghe P, Liston A, Boeckxstaens GE. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology. 2016 Apr;150(4):875-87.e9. doi: 10.1053/j.gastro.2015.12.034. Epub 2016 Jan 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2012
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Irritable Bowel Syndrome (ROME III criteria)
  • age 18-65 years

Exclusion Criteria:

  • medication: antidepressants or H1-receptor antagonists
  • pregnancy, breast feeding
  • co-morbidity: severe kidney- and/or liver disease
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Guy Boeckxstaens, Katholieke Universiteit Leuven
Katholieke Universiteit Leuven
Not Provided
Principal Investigator: Guy Boeckxstaens, M.D. Catholic University Leuven
Katholieke Universiteit Leuven
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP